Clinical Trial Categories
  • Age & Physical Activity (1)
  • Alzheimer's Disease (7)
  • Arthritis (3)
  • Asthma (1)
  • Cancer - Bladder (1)
  • Cancer - Brain & CNS (16)
  • Cancer - Breast (8)
  • Cancer - Colon/Colorectal (2)
  • Cancer - Digestive System (2)
  • Cancer - Female Reproductive (8)
  • Cancer - Gastric (1)
  • Cancer - Kidney (2)
  • Cancer - Leukemia (6)
  • Cancer - Liver (1)
  • Cancer - Lung (3)
  • Cancer - Lymphoma (27)
  • Cancer - Melanoma (15)
  • Cancer - Mesothelioma (2)
  • Cancer - Myeloma (10)
  • Cancer - Other (5)
  • Cancer - Ovarian (2)
  • Cancer - Pancreas (2)
  • Cancer - Peritoneal (5)
  • Cancer - Prostate (12)
  • Cancer - Sarcoma (1)
  • Cancer - Stomach (1)
  • Cancer - Testicular (1)
  • Cancer - Tissue (6)
  • Crohn's Disease (3)
  • Dermatitis (2)
  • Dermatomyositis (1)
  • Healthy (6)
  • Hepatitis C (2)
  • HIV (4)
  • HPV (1)
  • Hypercholesterolemia (1)
  • Immune Disease - Autoimmune (9)
  • Immune Disease - Primary (2)
  • Immune Disease - Secondary (6)
  • Infectious Disease (2)
  • Inflammatory Disease (3)
  • Kidney Transplant (1)
  • Liver Disease (2)
  • Lupus Erythematosus (3)
  • Multiple Sclerosis (3)
  • Neurodegenerative (1)
  • OX40 (1)
  • Parkinson's Disease (1)
  • Pediatric (3)
  • Transplant (2)
Friday
Oct092015

NCT02579252

24 Months Safety and Efficacy Study of AADvac1 in Patients with Mild Alzheimer's Disease (ADAMANT)

A 24 Months Randomised, Placebo-controlled, Parallel Group, Double Blinded, Multi Centre, Phase 2 Study to Assess Safety and Efficacy of AADvac1 Applied to Patients With Mild Alzheimer's Disease

Condition: Alzheimer's Disease
Sponsor: Axon Neuroscience SE
Phase 2 

Date: DateOctober 9, 2015
Categories CategoryAlzheimer's Disease
Tags ,

PrintView Printer Friendly Version